Assignee
HANGZHOU CONVERD CO LTD
CN·8 granted patents·6 pending applications·1 citations·filing 2016–2025
Top patents by PatentIndex Score
14 records- 0167US2024100106A1Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancersHANGZHOU CONVERD CO LTD·Filed 2023·Application pending·0 cites
- 0266US2022339220A1Therapeutic agents comprising oncolytic vaccinia viruses and nk cells, and uses thereof for drugs for treatment of tumors and/or cancersHANGZHOU CONVERD CO LTD·Filed 2022·Application pending·0 cites
- 0365US10980859B2In vivo individualized systemic immunotherapeutic method and deviceHANGZHOU CONVERD CO LTD·Filed 2016·Granted Apr 20, 2021·1 cites·9 claims
- 0462US12329826B2Therapeutic agents comprising nucleic acids and CAR-modified immune cells, and uses thereofHANGZHOU CONVERD CO LTD·Filed 2019·Granted Jun 17, 2025·0 cites·17 claims
- 0562US2026048139A1Therapeutic agents comprising nucleic acids and car-modified immune cells, and uses thereofHANGZHOU CONVERD CO LTD·Filed 2025·Application pending·0 cites
- 0660US11819519B2Therapeutic agents comprising nucleic acids and TCR modified immune cells and uses thereofHANGZHOU CONVERD CO LTD·Filed 2019·Granted Nov 21, 2023·0 cites·15 claims
- 0760US11806374B2Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancersHANGZHOU CONVERD CO LTD·Filed 2018·Granted Nov 7, 2023·0 cites·26 claims
- 0860US11446345B2Therapeutic agents and uses thereof for drugs for treatment of tumors and/or cancersHANGZHOU CONVERD CO LTD·Filed 2018·Granted Sep 20, 2022·0 cites·15 claims
- 0956US2023265396A1Isolated recombinant oncolytic poxvirus capable of being regulated and controlled by microrna and use thereofHANGZHOU CONVERD CO LTD·Filed 2021·Application pending·0 cites
- 1053US11786552B2Therapeutic compositions and applications that comprise nucleic acids and adoptively transferred immune cellHANGZHOU CONVERD CO LTD·Filed 2020·Granted Oct 17, 2023·0 cites·13 claims
- 1151US12486487B2Method for producing a virus and a harvesting solution compositionHANGZHOU CONVERD CO LTD·Filed 2020·Granted Dec 2, 2025·0 cites·20 claims
- 1243US2020289591A1Isolated Recombinant Oncolytic Poxvirus, Pharmaceutical Composition, and Use Thereof in Treatment of Tumors and/or CancerHANGZHOU CONVERD CO LTD·Filed 2018·Application pending·0 cites
- 1341US11357804B2Application of oncolytic viruses as immunostimulants for treatment of tumors and/or cancersHANGZHOU CONVERD CO LTD·Filed 2018·Granted Jun 14, 2022·0 cites·5 claims
- 1436US2020020420A1Method for Establishing Machine Learning Model for Predicting Toxicity of siRNA to Certain Type of Cells and Application ThereofHANGZHOU CONVERD CO LTD·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when HANGZHOU CONVERD CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →